2024
670P Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Aperribay E, Wolf J, Villaruz L, Studeny M, Bouzaggou M, Fang X, Morgensztern D. 670P Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data. Annals Of Oncology 2024, 35: s525-s526. DOI: 10.1016/j.annonc.2024.08.736.Peer-Reviewed Original Research
2023
75MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts
Kuboki Y, Gambardella V, Castillon J, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Wolf J, Owonikoko T, Studeny M, Bouzaggou M, Song E, Wermke M. 75MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts. Annals Of Oncology 2023, 34: s1495. DOI: 10.1016/j.annonc.2023.10.210.Peer-Reviewed Original ResearchPhase I trialI trial